Evidence map›Paper›PMID 41601916›Full record

ArticleJAMIA open2026

Physiological foundation modeling for subclinical disease assessment: a prospective pilot.

William Yuan, Shiwei Xu, Sara Dionisi, Katharine von Herrmann, Kate Frederick-Dyer, Joyce Cheung-Flynn, Caleb Kennedy, Charles R Flynn, Scott Lipnick

Abstract read
In one paragraph

Article in JAMIA open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

William YuanEtiome Inc, Cambridge, MA, 02142, United States.
Shiwei XuEtiome Inc, Cambridge, MA, 02142, United States.
Sara DionisiFlagship Pioneering, Cambridge, MA, 02142, United States.
Katharine von HerrmannEtiome Inc, Cambridge, MA, 02142, United States.
Kate Frederick-DyerDepartment of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, United States.
Joyce Cheung-FlynnDepartment of Vascular Surgery, Vanderbilt University Medical Center, Nashville, TN, 37232, United States.
Caleb KennedyEtiome Inc, Cambridge, MA, 02142, United States.
Charles R FlynnDepartment of Surgery, Vanderbilt University Medical Center, Nashville, TN, 37232, United States.
Scott LipnickEtiome Inc, Cambridge, MA, 02142, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Clinical studies struggle to locate the right patients, in part because many remain undiagnosed or lack relevant labels. We develop and prospectively test a physiology-based patient representation ("Bioprofile") to evaluate whether it can reduce the number of individuals who must be screened and enable more precise targeting of candidates for steatotic liver disease studies. Materials and Methods: We trained Bioprofile patient representations from routinely collected health data and fine-tuned against multiple endpoints. Bioprofiles were trained using 1 million subjects from the UK Biobank and other cohorts. The trained model was applied to 45 484 research subjects at Vanderbilt University Medical Center. Based on Bioprofile nominations, 31 subjects were recruited for a prospective validation study. The primary outcome measure was proton density fat fraction (PDFF), an imaging-based metric of steatosis severity. Results: Bioprofile models achieved a Spearman coefficient of 0.65 against PDFF, outperforming existing foundation models (ρ = 0.361) and clinical risk scores ( Discussion and Conclusion: Artificial intelligence (AI)-based profiling of patient physiology can reveal individuals who have subclinical signatures of disease. If implemented widely, this approach can identify unknown human subjects, reduce screening failures, and improve trial quality. Bioprofiles may have additional utility in decision support applications in precision medicine and AI-augmented healthcare.

Indexed as

clinical trialsliver steatosispatient representations

Identifiers

PMID41601916
PMCPMC12832941

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.